| 227 | 0 | 111 |
| 下载次数 | 被引频次 | 阅读次数 |
流行性感冒（简称“流感”）是由流感病毒引起的一种急性呼吸道传染病，传染性强，发病率高，具有全球分布特性，是受到全球关注的重要公共卫生问题。尽管流感多可自愈，但在高危人群中也可能引起严重并发症，甚至危及生命。在目前已知的4种类型的流感病毒中，甲型和乙型流感病毒在人群中呈季节性流行，其中甲型流感病毒危害性最大，其在全球范围内的检测率超过了乙型流感病毒。迄今为止，已有多种抗流感病毒药物应用于临床流感的治疗，但由于流感病毒的突变性和耐药性，现有抗流感病毒药物的有效性降低。抗流感病毒药物联合治疗具有潜在价值，不同作用机制的药物联合使用可能会增加药物的协同性，降低药物的耐药性，为临床提供新的药物治疗方案。该综述系统梳理了当前抗流感病毒药物的联用情况，探讨了药物联合应用的价值，为临床提供参考。
Abstract：Influenza is an acute respiratory infectious disease caused by influenza viruses, characterized by high infectivity, high incidence, and global distribution. It is a major public health issue of global concern. Although influenza is often self-limiting, it may cause severe complications and even be life-threatening in high-risk populations. Among the 4 known types of influenza viruses, influenza A and B viruses are responsible for seasonal epidemics in humans, with influenza A virus posing the greatest threat. Its surveillance detection rate on a global scale has surpassed that of influenza B virus. Although multiple classes of antiviral agents against influenza have been deployed clinically, the efficacy of existing therapeutics is progressively compromised by viral mutation and the emergence of drug resistance. Combination therapy with antiviral agents against influenza represents a promising strategy, where the deployment of mechanistically distinct drugs may enhance synergistic effects, delay the emergence of resistance, and provide novel therapeutic approaches for advanced patient care. This review critically examines current combinatorial regimens of antiviral agents against influenza, explores the therapeutic value of drug synergy, and provides a reference for clinical practice.
[1]吕菁君,赵光举,赵宏宇,等.成人流行性感冒诊疗规范急诊专家共识(2022版)[J].中国急救医学,2022,42(12):1013.
[2]CAINI S,KUSZNIERZ G,GARATE V V,et al.The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century[J].PLoS One,2019,14(9):e0222381.
[3]DHANASEKARAN V,SULLIVAN S,EDWARDS K M,et al.Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination[J].Nat Commun,2022,13(1):1721.
[4]DE CLERCQ E.Antiviral agents active against influenza A viruses[J].Nat Rev Drug Discov,2006,5(12):1015.
[5]SNELL N J.Ribavirin:current status of a broad spectrum antiviral agent[J].Expert Opin Pharmacother,2001,2(8):1317.
[6]DUVAL X,VAN DER WERF S,BLANCHON T,et al.Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza:a randomized placebo-controlled trial[J].PLoS Med,2010,7(11):e1000362.
[7]ESCURET V,CORNU C,BOUTITIE F,et al.Oseltamivirzanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H INI)virus infections[J].Antiviral Res,2012,96(2):130.
[8]PIZZORNO A,ABED Y,RHéAUME C,et al.Oseltamivirzanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2)and A(H1N1)pdm09 viruses[J].Antiviral Res,2014,105:54.
[9]PETERSEN E,KELD D B,ELLERMANN-ERIKSEN S,et al.Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator-and ECMO-treated critically ill patients with pandemic influenza A(H1N1)v[J].Scand J Infect Dis,2011,43(6-7):495.
[10]CARRAT F,DUVAL X,TUBACH F,et al.Effect of oseltamivir,zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households[J].Antivir Ther,2012,17(6):1085.
[11]PIRES DE MELLO C P,DRUSANO G L,ADAMS J R,et al.Oseltamivir-zanamivir combination therapy suppresses drugresistant H1N1 influenza A viruses in the hollow fiber infection model(HFIM)system[J].Eur J Pharm Sci,2018,111:443.
[12]ZHANG Y,GAO H N,LIANG W F,et al.Efficacy of oseltamivirperamivir combination therapy compared to oseltamivir monotherapy for influenza A(H7N9)infection:a retrospective study[J].BMC Infect Dis,2016,16:76.
[13]刘雅芬,高燕.免疫抑制患者流感病毒感染的抗病毒治疗策略及耐药研究进展[J].中华临床感染病杂志,2022,15(2):145.
[14]SMEE D F,HURST B L,WONG M H,et al.Combinations of oseltamivir and peramivir for the treatment of influenza A(H1N1)virus infections in cell culture and in mice[J].Antiviral Res,2010,88(1):38.
[15]时晓光.帕拉米韦与奥司他韦治疗儿童甲型流感的临床效果对比[J].中国保健营养,2021,31(2):174.
[16]CHECKMAHOMED L,PADEY B,PIZZORNO A,et al.In vitro combinations of baloxavir acid and other inhibitors against seasonal influenza A viruses[J].Viruses,2020,12(10):1139.
[17]GOVORKOVA E A,FANG H B,TAN M,et al.Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells[J].Antimicrob Agents Chemother,2004,48(12):4855.
[18]SIMEONOVA L,GEGOVA G,GALABOV A S.Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A(H3N2)infection in mice[J].Antiviral Res,2012,95(2):172.
[19]MEIJER W J,KROMDIJK W,VAN DEN BROEK M P H,et al.Treatment of immunocompromised,critically ill patients with influenza a H1N1 infection with a combination of oseltamivir,amantadine,and zanamivir[J].Case Rep Infect Dis,2015,20 15:504975.
[20]国家呼吸系统疾病临床医学研究中心,中华医学会儿科学分会呼吸学组.儿童流感诊断与治疗专家共识(2020年版)[J].中华实用儿科临床杂志,2020,35(17):1281.
[21] Centers For Disease Control and Prevention.Antiviral drug resistance among influenza viruses[EB/OL].(2024-10-09)[2025-03-21].https://www.cdc.gov/flu/hcp/antivirals/antivirald rug-resistance.html.
[22]黄金祝.奥司他韦+阿比多尔治疗小儿乙型流感的效果[J].中外医疗,2022,41(9):102.
[23]周西笛,徐巧芸,黎德郡.阿比多尔联合奥司他韦治疗流感的临床疗效分析[J].健康必读,2021(20):65.
[24]张龙升,林建英,黄姗姗.阿比多尔联合奥司他韦治疗对流感患者的临床效果分析[J].中外医疗,2024,43(14):98.
[25]FUKAO K,NOSHI T,YAMAMOTO A,et al.Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection[J].J Antimicrob Chemother,2019,74(3):654.
[26]PARK J H,KIM B,ANTIGUA K J C,et al.Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model[J].Antiviral Res,2021,193:105126.
[27]NTEM-MENSAH A D,HEIL E,PAJOUMAND M,et al.2256.Baloxavir marboxil in combination with oseltamivir in two critically ill patients with influenza A(H1N1;2009 strain)on veno-venous extra-corporal membranous oxygenation[J].Open Forum Infect Dis,2019,6(Supplement 2):S772.
[28]KUMAR D,ISON M G,MIRA J P,et al.Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza(FLAGSTONE):a randomised,parallel-group,double-blind,placebo-controlled,superiority trial[J].Lancet Infect Dis,2022,22(5):718.
[29]WANG Y M,FAN G H,SALAM A,et al.Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection[J].J Infect Dis,2020,221(10):1688.
[30]ORMOND L,LIU P,MATUSZEWSKI S,et al.The combined effect of oseltamivir and favipiravir on influenza A virus evolution[J].Genome Biol Evol,2017,9(7):1913.
[31]BAZ M,CARBONNEAU J,RHéAUME C,et al.Combination therapy with oseltamivir and favipiravir delays mortality but does not prevent oseltamivir resistance in immunodeficient mice infected with pandemic A(H1N1)influenza virus[J].Viruses,2018,10(11):610.
[32]MU S R,ZOU X H,WANG YM,et al.The combined effect of oseltamivir and favipiravir on influenza A virus evolution in patients hospitalized with severe influenza[J].Antiviral Res,2023,216:105657.
[33]LUMBY C K,ZHAO L,OPORTO M,et al.Favipiravir and zanamivir cleared infection with influenza B in a severely immunocompromised child[J].Clin Infect Dis,2020,71(7):e191.
[34]SMEE D F,HURST B L,WONG M H,et al.Effects of double combinations of amantadine,oseltamivir,and ribavirin on influenza A(H5N1)virus infections in cell culture and in mice[J].Antimicrob Agents Chemother,2009,53(5):2120.
[35]NGUYEN J T,HOOPES J D,LE M H,et al.Triple combination of amantadine,ribavirin,and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro[J].PLoS One,2010,5(2):e9332.
[36]KIM W Y,SUH G Y,HUH J W,et al.Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation[J].Antimicrob Agents Chemother,2011,55(12):5703.
[37]SEO S,ENGLUND J A,NGUYEN J T,et al.Combination therapy with amantadine,oseltamivir and ribavirin for influenza A infection:safety and pharmacokinetics[J].Antivir Ther,2013,18(3):377.
[38]BEIGEL J H,BAO Y J,BEELER J,et al.Oseltamivir,amantadine,and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza:a multicentre,doubleblind,randomised phase 2 trial[J].Lancet Infect Dis,2017,17(12):1255.
[39]苏兴栋,磷酸奥司他韦联合利巴韦林对甲型H1N1流感患儿流感病毒转阴率及不良反应的影响[J].医学理论与实践,2020,33(4):620.
[40]郭玉峰.磷酸奥司他韦与利巴韦林配合对甲型H1N1流感患儿的影响研究[J].系统医学,2021,6(1):162.
[41]甘婷婷,沈文强.连花清瘟胶囊联合磷酸奥司他韦治疗热毒犯肺证甲型H1N1流感临床研究[J].新中医,2023,55(2):69.
[42]杜亚哲,肖少伟.银翘散联合磷酸奥司他韦治疗甲型流感的临床效果及对淋巴细胞亚群的影响[J].中国药物与临床,2024,24(4):221.
[43]卢壮丽.小儿豉翘清热颗粒联合帕拉米韦对儿童流感的疗效观察[J].医学理论与实践,2023,36(7):1183.
[44]王俊华.分析磷酸奥司他韦颗粒与喜炎平注射液联合治疗儿童乙型流感的效果[J].中国实用医药,2024,19(16):111.
[45]甘考,成业,陈韵,等.中医药联合抗流感毒药物治疗甲型流感的回顾性研究[J].长春中医药大学学报,2023,39(2):171.
[46]QIN J A,YANG Y H,AI C,et al.Antibiotic combinations prediction based on machine learning to multicentre clinical data and drug interaction correlation[J].Int J Antimicrob Agents,2024,63(5):107122.
基本信息:
DOI：10.19577/j.1007-4406.2026.01.018
中图分类号:R978.7
引用信息:
[1]许海鑫,刘昕竹,姚昀璐,等.抗流感病毒药物联合应用的研究进展[J].中国临床药学杂志,2026,35(01):91-96.DOI:10.19577/j.1007-4406.2026.01.018.
2026-01-25
2026-01-25